Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

Movement Disorders

Volumn 20, Issue 8, 2005, Pages 958-963

  Ondo, William G ^a   Tintner, Ron ^a   Voung, Kevin Dat ^a   Lai, Dejian ^b   Ringholz, George ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hallucinations; Parkinson's disease; Psychosis; Quetiapine

Indexed keywords

CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; PLACEBO; QUETIAPINE;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PARALLEL DESIGN; PARKINSON DISEASE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEDATION; SIDE EFFECT; VISUAL HALLUCINATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PLACEBOS; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 26444597010     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20474     Document Type: Article

References (45)

1. Naimark D, Jackson E, Rockwell E, Jeste DV. Psychotic symptoms in Parkinson's disease patients with dementia. [comment]. J Am Geriatr Soc 1996;44:296-299.
2. Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999;56:595-601.
3. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995;65:115-138.
4. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996;53:1265-1268.
5. Godwin-Austen RB. Psychosis and hallucinations in Parkinson's disease. Adv Neurol 1999;80:401-402.
6. Anderson KE, Weiner WJ. Psychiatric symptoms in Parkinson's disease. Curr Neurol Neurosci Rep 2002;2:303-309.
7. Naimark D, Jackson E, Rockwell E, Jeste DV. Psychotic symptoms in Parkinson's disease patients with dementia. J Am Geriatr Soc 1996;44:296-299.
8. Goodwin FK. Psychiatric side effects of levodopa in man. JAMA 1971;218:1915-1920.
9. Nissenbaum H, Quinn NP, Brown RG, Toone B, Gotham AM, Marsden CD. Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. Psychol Med 1987;17:899-904.
10. Arnulf I, Bonnet AM, Damier P, et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. [comment]. Neurology 2000;55:281-288.
11. Fischer P, Danielczyk W, Simanyi M, Streifler MB. Dopaminergic psychosis in advanced Parkinson's disease. Adv Neurol 1990;53: 391-397.
12. Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol 1998;21:289-295.
13. Giladi N, Treves TA, Paleacu D, et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. J Neural Transm 2000;107:59-71.
14. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-671.
15. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-2229.
16. Klein C, Gordon J, Pollak L, Rabey JM. Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clin Neuropharmacol 2003;26:8-11.
17. Anonymous. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med 1999;340:757-763.
18. Anonymous. Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group. Lancet 1999;353:2041-2042.
19. Leopold NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord 2000;15:301-304.
20. Meco G, Alessandri A, Giustini P, Bonifati V. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Mov Disord 1997;12:610-612.
21. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995;56:556-559.
22. Rudolf J, Ghaemi M, Schmulling S. Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine. Eur Psychiatry 1999;14:356-357.
23. Jimenez-Jimenez FJ, Tallon-Barranco A, Orti-Pareja M, Zurdo M, Porta J, Molina JA. Olanzapine can worsen parkinsonism. Neurology 1998;50:1183-1184.
24. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002;52:438-445.
25. Morgante L, Epifanio A, Spina E, et al. Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. Neurol Sci 2002; 23(Suppl. 2):S89-S90.
26. Hellewell JS. Quetiapine: a well-tolerated and effective atypical antipsychotic. Hosp Med (Lond) 2002;63:600-603.
27. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients [see comments]. Neurology 2000;55:789-794.
28. Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002;17:1031-1035.
29. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003;18:510-514.
30. Kodama R, Morita S, Miwa H, Kondo T. Three patients with Parkinson's disease whose therapeutic levels were successfully improved after administration of quetiapine for suppression of psychosis. No To Shinkei 2003;55:413-417.
31. Onor ML, Saina M, De Vanna M, Aguglia E. Efficacy of quetiapine in the treatment of behavioral symptoms in dementia. Eur Psychiatry 2002;17(Suppl. 1):131.
32. Targum SD, Abbott JL. Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol 2000;20:54-60.
33. Menza MM, Palermo B, Mark M. Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease. Ann Clin Psychiatry 1999;11:141-144.
34. Parsa MA, Bastani B. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1998;10:216-219.
35. Mancini F, Tassorelli C, Martignoni E, et al. Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease. Clin Neuropharmacol 2004;27:33-37.
36. Martinez-Martin P, Gil-Nagel A, Gracia LM, Gomez JB, Martinez-Sarries J, Bermejo F. Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord 1994;9:76-83.
37. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment.[see comment]. Mov Disord 1994;9:390-394.
38. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001;158:360-369.
39. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-293.
40. Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist [see comments]. Neurology 1995;45:1305-1308.
41. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 2002;25:107-110.
42. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001;16:1171-1174.
43. Farver DK, Khan MH. Zolpidem for antipsychotic-induced parkinsonism. Ann Pharmacother 2001;35:435-437.
44. Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry 2002;63:513-515.
45. Reddy S, Factor SA, Molho ES, Feustel PJ. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002;17:676-681.